Back Back
Cell No. : Cell Name
RCB1548 : JHUEM-1  update : 2024/06/13
CommentHuman cell line derived from uterine endometrioid adenocarcinoma. Said CA125 and CEA producing. Application consideration
Comment from the depositor
Terms and conditionsA prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
approver's address
Contact Us
RIKEN, BioResource Research Center
Cell Engineering Division
Dr.ISHIKAWA Hiroshi (Cell Bank)
Fax. +81-29-836-9130
Order Form Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Ishikawa, Hiroshi
Originator Ishikawa, H. & Yasuda, M.
Year of deposit 1999
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 56 years
Tissue uterus
Disease name Endometrioid adenocarcinoma G2
Metastatic ability No
Classification cancer
Year of origin 1998
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_4655
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium DMEM/HamF12 + 15% FBS
Antibiotics Free
Passage method (0.05% Trypsin + 0.02% EDTA) or (0.25% Trypsin + 0.04% EDTA)
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
Chromosome mode 86-94(50) : /88(8),89(7),90(10),91(11),92(4),93(5)/
STR(human) OK
deposit info
lot info
Reference information Reference 0
User's Publication 4

To topTop

To topTop
User's Publication
21801  Takaki EO, Kiyono K, Obuchi Y, Yamauchi T, Watanabe T, Matsumoto H, Karimine M, Kuniyoshi Y, Nishikori S, Yokoyama F, Nishimori H, Nabeshima H, Nakamura K.  A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors.  Clin Cancer Res  2024    PubMed ID: 38864850   DOI: 10.1158/1078-0432.CCR-24-0096
20137  Ito Y, Terao Y, Noma S, Tagami M, Yoshida E, Hayashizaki Y, Itoh M, Kawaji H.  Nanopore sequencing reveals TACC2 locus complexity and diversity of isoforms transcribed from an intronic promoter.  Sci Rep  2021  11(1):9355  PubMed ID: 33931666   DOI: 10.1038/s41598-021-88018-9
12164  Mary Ellen Urick, Daphne W. Bell  Proteomic profiling of FBXW7‐mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target  ORIGINAL RESEARCH  2020    PubMed ID: 32248654   DOI: 10.1002/cam4.3013
8772  Sugimoto T, Koizumi T, Sudo T, Yamaguchi S, Kojima A, Kumagai S, Nishimura R.  Correlative expression of cyclooxygenase-1 (Cox-1) and human epidermal growth factor receptor type-2 (Her-2) in endometrial cancer.  Kobe J Med Sci  2007  53:177-87  PubMed ID: 18204294  

Back Back Return Top Page